Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CohBar Inc

Healthcare US CWBR

NoneUSD
0.00(0%)

Last update at 2025-02-27T10:04:08.008183Z

Day Range

--
LowHigh

52 Week Range

0.513.59
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap2.21M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.02815M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-4.37

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -12.17521M -15.47578M -16.26496M -13.04477M -15.70586M
Minority interest - - - - 0.00000M
Net income -11.96212M -15.40806M -14.63352M -13.64914M -15.70586M
Selling general administrative 6.45M 7.70M 6.26M 5.95M 5.30M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.10M 0.14M 0.16M 0.15M 0.08M
Ebit -12.38830M -15.40816M -13.19951M -12.58303M -15.22784M
Ebitda -12.06576M -15.40258M -15.44905M -12.29272M -15.14872M
Depreciation and amortization 0.32M 0.00558M -2.24954M 0.29M 0.08M
Non operating income net other - - -2.75404M -0.14954M -0.13954M
Operating income -12.38830M -15.40816M -13.19951M -12.58303M -15.33433M
Other operating expenses 12.39M 15.41M 13.20M 12.58M 15.33M
Interest expense 0.01M 0.07M 0.82M 0.75M 0.56M
Tax provision - - - - -
Interest income 0.22M 0.00558M 0.04M 0.29M 0.19M
Net interest income 0.21M -0.06762M -0.77476M -0.46174M -0.37154M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -0.21309M -0.06771M -1.63145M 0.60M 0.37M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 12.39M 15.41M 13.20M 12.58M 15.33M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.21M -0.06762M -3.06545M -0.46174M -0.37154M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -12.17521M -15.47578M -16.26496M -13.04477M -15.70586M
Net income applicable to common shares -12.17521M -15.47578M -16.26496M -13.04477M -15.70586M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 16.37M 27.30M 21.91M 13.53M 23.04M
Intangible assets 0.02M 0.02M 0.02M 0.02M 0.02M
Earning assets - - - - -
Other current assets 0.45M 21.95M 18.53M 0.36M 0.26M
Total liab 1.03M 1.69M 3.42M 5.40M 5.08M
Total stockholder equity 15.33M 25.61M 18.49M 8.14M 17.96M
Deferred long term liab - - - - 0.00000M
Other current liab 0.85M 0.95M 2.00M 1.59M 1.02M
Common stock 0.00291M 0.09M 0.06M 0.04M 0.04M
Capital stock 0.00291M 0.09M 0.06M 0.04M 0.04M
Retained earnings -96.90927M -84.73406M -69.25829M -52.99332M -39.94855M
Other liab - - - - 0.00000M
Good will - - - - 0.00000M
Other assets 0.06M 0.07M 0.07M 0.06M 0.06M
Cash 5.93M 4.99M 2.89M 12.56M 5.72M
Cash and equivalents - - - - -
Total current liabilities 1.03M 1.69M 3.07M 2.04M 2.16M
Current deferred revenue - - - - -
Net debt -5.93073M -4.62587M -2.19639M -9.20767M -2.80600M
Short term debt - 0.37M 0.35M - 0.00000M
Short long term debt - 0.37M 0.35M - 0.00000M
Short long term debt total - 0.37M 0.70M 3.36M 2.92M
Other stockholder equity 112.24M 110.26M 87.68M 61.09M 58.10M
Property plant equipment 0.07M 0.26M 0.39M 0.52M 0.52M
Total current assets 16.22M 26.95M 21.43M 12.93M 22.44M
Long term investments - - - - 0.00000M
Net tangible assets 15.31M 25.59M 18.47M 8.12M 17.94M
Short term investments 9.81M 21.25M 18.12M 0.00000M 16.46M
Net receivables 0.03M 0.17M - - -
Long term debt - - 0.35M 3.36M 2.92M
Inventory - -21.42737M - - 0.00000M
Accounts payable 0.18M 0.37M 0.73M 0.44M 1.14M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - -0.37651M -0.22990M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 0.06M 0.04M 0.04M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - -69.25829M -52.99332M -39.94855M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 0.06M 0.07M 0.07M 0.06M 0.06M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 0.15M 0.35M 0.48M 0.61M 0.60M
Capital lease obligations - - - - 0.00000M
Long term debt total - - 0.35M 3.36M 2.92M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 11.52M -3.14297M -18.15207M 16.50M -10.86100M
Change to liabilities -0.19189M -0.35561M 0.28M -0.12299M 0.92M
Total cashflows from investing activities 11.52M -3.14297M -18.15207M 16.34M -11.29249M
Net borrowings -0.37500M -0.36500M -0.36500M -0.36500M 3.84M
Total cash from financing activities -0.13950M 19.69M 18.26M 0.61M 24.32M
Change to operating activities 0.12M -1.33193M 1.03M 0.47M 0.17M
Net income -12.17521M -15.47578M -16.26496M -13.04477M -15.70586M
Change in cash 0.94M 2.10M -9.66928M 6.84M 2.90M
Begin period cash flow 4.99M 2.89M 12.56M 5.72M 2.82M
End period cash flow 5.93M 4.99M 2.89M 12.56M 5.72M
Total cash from operating activities -10.44649M -14.44719M -9.77847M -10.10610M -10.13038M
Issuance of capital stock 0.22M 17.98M 17.96M 0.00000M 19.30M
Depreciation 0.10M 0.14M 0.16M 0.15M 0.08M
Other cashflows from investing activities 0.00605M -0.00222M -0.00316M -0.00745M -0.00815M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - - - - 0.00000M
Sale purchase of stock - - 0.25M 0.55M 19.80M
Other cashflows from financing activities 0.02M 2.07M 0.30M 0.61M 5.02M
Change to netincome 1.69M 2.54M 4.51M 2.61M 4.32M
Capital expenditures 0.00000M 0.00876M 0.03M 0.15M 0.42M
Change receivables - - - - 0.00000M
Cash flows other operating - - 2.24M -0.13525M -0.06677M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - -9.66928M 6.84M 2.90M
Change in working capital -0.06899M -1.68754M 1.32M -0.22367M 0.82M
Stock based compensation 1.66M 2.54M 2.22M 2.61M 4.32M
Other non cash items 0.03M 0.03M 2.80M 0.41M 0.35M
Free cash flow -10.44649M -14.45595M -9.80438M -10.25565M -10.55372M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CWBR
CohBar Inc		 - -% - - - - 0.27 -3.2372
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

CohBar Inc

1455 Adams Drive, Menlo Park, CA, United States, 94025

Key Executives

Name Title Year Born
Dr. Joseph J. Sarret J.D., M.D. CEO & Director 1967
Dr. Pinchas Cohen Dean, M.D. Founder & Member of Scientific Advisory Board 1957
Dr. Nir Yacov Barzilai M.D. Founder & Member of Scientific Advisory Board 1956
Prof. John M. Amatruda M.D., Ph.D. Co-Founder & Member of Scientific Advisory Board 1945
Mr. Jeffrey F. Biunno CPA, CPA, M.B.A., MBA CFO, Treasurer & Sec. 1966
Ms. Jordyn Tarazi Director of Investor Relations NA
Dr. Kent Grindstaff Ph.D. Sr. VP of Research NA
Dr. Nick Vlahakis MBBS Acting Chief Medical Officer NA
Dr. John M. Amatruda M.D., Ph.D. Co-Founder 1946

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions